| Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice NE Kohl, CA Omer, MW Conner, NJ Anthony, JP Davide, SJ Desolms, ... Nature medicine 1 (8), 792-797, 1995 | 717 | 1995 |
| A non–D2-receptor-binding drug for the treatment of schizophrenia KS Koblan, J Kent, SC Hopkins, JH Krystal, H Cheng, R Goldman, ... New England Journal of Medicine 382 (16), 1497-1506, 2020 | 248 | 2020 |
| Receptor Activity-modifying Protein 1 Determines the Species Selectivity of Non-peptide CGRP Receptor Antagonists* 210 JJ Mallee, CA Salvatore, B LeBourdelles, KR Oliver, J Longmore, ... Journal of Biological Chemistry 277 (16), 14294-14298, 2002 | 243 | 2002 |
| A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis RE Barrington, MA Subler, E Rands, CA Omer, PJ Miller, JE Hundley, ... Molecular and cellular biology 18 (1), 85-92, 1998 | 218 | 1998 |
| Pharmacological characterization of MK-0974 [N-[(3R, 6S)-6-(2, 3-difluorophenyl)-2-oxo-1-(2, 2, 2-trifluoroethyl) azepan-3-yl]-4-(2-oxo-2, 3-dihydro-1H-imidazo [4, 5-b] pyridin … CA Salvatore, JC Hershey, HA Corcoran, JF Fay, VK Johnston, EL Moore, ... Journal of pharmacology and experimental therapeutics 324 (2), 416-421, 2008 | 179 | 2008 |
| High throughput ion-channel pharmacology: planar-array-based voltage clamp L Kiss, PB Bennett, VN Uebele, KS Koblan, SA Kane, B Neagle, ... Assay and Drug Development Technologies 1 (1, Supplement 2), 127-135, 2003 | 170 | 2003 |
| Potent, Orally Bioavailable Calcitonin Gene-Related Peptide Receptor Antagonists for the Treatment of Migraine: Discovery of N-[(3R,6S)-6-(2,3-Difluorophenyl)-2-oxo-1- (2,2,2 … DV Paone, AW Shaw, DN Nguyen, CS Burgey, JZ Deng, SA Kane, ... Journal of medicinal chemistry 50 (23), 5564-5567, 2007 | 159 | 2007 |
| Localization of a Binding Site for Phosphatidylinositol 4, 5-Bisphosphate on Human Profilin (∗) RH Sohn, J Chen, KS Koblan, PF Bray, PJ Goldschmidt-Clermont Journal of Biological Chemistry 270 (36), 21114-21120, 1995 | 158 | 1995 |
| Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl: protein transferase and geranylgeranyl: protein transferase type-I RB Lobell, D Liu, CA Buser, JP Davide, E DePuy, K Hamilton, KS Koblan, ... Molecular cancer therapeutics 1 (9), 747-758, 2002 | 155 | 2002 |
| SEP-363856, a novel psychotropic agent with a unique, non-D2 receptor mechanism of action N Dedic, PG Jones, SC Hopkins, R Lew, L Shao, JE Campbell, KL Spear, ... Journal of Pharmacology and Experimental Therapeutics 371 (1), 1-14, 2019 | 149 | 2019 |
| Mouse Mammary Tumor Virus-Ki-rasB Transgenic Mice Develop Mammary Carcinomas That Can Be Growth-inhibited by a Farnesyl:Protein Transferase Inhibitor CA Omer, Z Chen, RE Diehl, MW Conner, HY Chen, ME Trumbauer, ... Cancer research 60 (10), 2680-2688, 2000 | 142 | 2000 |
| Design, Synthesis, and Evaluation of a Novel 4-Aminomethyl-4-fluoropiperidine as a T-Type Ca2+ Channel Antagonist WD Shipe, JC Barrow, ZQ Yang, CW Lindsley, FV Yang, KAS Schlegel, ... Journal of medicinal chemistry 51 (13), 3692-3695, 2008 | 140 | 2008 |
| Cloning, characterization and central nervous system distribution of receptor activity modifying proteins in the rat KR Oliver, SA Kane, CA Salvatore, JJ Mallee, AM Kinsey, KS Koblan, ... European Journal of Neuroscience 14 (4), 618-628, 2001 | 137 | 2001 |
| Orexin receptor antagonism prevents transcriptional and behavioral plasticity resulting from stimulant exposure CJ Winrow, KQ Tanis, DR Reiss, AM Rigby, JM Uslaner, VN Uebele, ... Neuropharmacology 58 (1), 185-194, 2010 | 126 | 2010 |
| In vitro characterization of T-type calcium channel antagonist TTA-A2 and in vivo effects on arousal in mice RL Kraus, Y Li, Y Gregan, AL Gotter, VN Uebele, SV Fox, SM Doran, ... Journal of Pharmacology and Experimental Therapeutics 335 (2), 409-417, 2010 | 125 | 2010 |
| Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omental arteries and in SK-N-MC cells L Edvinsson, R Alm, D Shaw, RZ Rutledge, KS Koblan, J Longmore, ... European journal of pharmacology 434 (1-2), 49-53, 2002 | 125 | 2002 |
| Functional and pharmacological properties of canine ERG potassium channels J Wang, K Della Penna, H Wang, J Karczewski, TM Connolly, KS Koblan, ... American Journal of Physiology-Heart and Circulatory Physiology 284 (1 …, 2003 | 123 | 2003 |
| 3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency IM Bell, SN Gallicchio, M Abrams, LS Beese, DC Beshore, ... Journal of medicinal chemistry 45 (12), 2388-2409, 2002 | 121 | 2002 |
| LRRTM3 promotes processing of amyloid-precursor protein by BACE1 and is a positional candidate gene for late-onset Alzheimer's disease J Majercak, WJ Ray, A Espeseth, A Simon, XP Shi, C Wolffe, K Getty, ... Proceedings of the National Academy of Sciences 103 (47), 17967-17972, 2006 | 110 | 2006 |
| Klebsiella pneumoniae nifM gene product is required for stabilization and activation of nitrogenase iron protein in Escherichia coli. KS Howard, PA McLean, FB Hansen, PV Lemley, KS Koblan, ... Journal of Biological Chemistry 261 (2), 772-778, 1986 | 108 | 1986 |
